Sutro Biopharma KOL Event
Virtual,
December 3, 2020
General Agenda
KOL Speakers:
Wendel Naumann, MD
Director, Minimally Invasive Surgery in Gynecologic Oncology
Professor, Department of Ob/Gyn at Atrium Health, Levine Cancer Institute
Lainie P. Martin, MD
Leader, Gynecology/Oncology Program
Associate Professor of Medicine, Hospital at University of Pennsylvania

Sutro Biopharma
[STRO]
US$925 MM MCap
FolRα-targeting ADC (STRO-002) Phase 1, additional dose escalation data in 4Q20. CD74-targeting ADC (STRO-001) Phase 1, additional dose escalation data in 4Q20. BMS collaboration Phase 1 clinical development update for CC-99712 (BCMA-targeting ADC). Merck collaboration update in 2020 on first cytokine derivative program. [more information]